Actively Recruiting
First-in-Human Study of AVZO-021 to Assess Safety, Pharmacokinetics, and Antitumor Activity Alone and With Other Therapies in Advanced Solid Tumors
Led by Avenzo Therapeutics, Inc. · Updated on 2026-09-28
430
Participants Needed
13
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying AVZO-021, an oral medication that inhibits cyclin-dependent kinase 2 CDK2, in patients with advanced solid tumors. This Phase 12, first-in-human, open-label, nonrandomized trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021. The study focuses on tumors including HRHER2- breast cancer and CCNE1 altered malignancies, where standard treatments may no longer be effective or safe. Participants receive escalating doses of AVZO-021 once daily in 28-day cycles as monotherapy or in combination with other cancer therapies such as fulvestrant, palbociclib, ribociclib, abemaciclib, sacituzumab govitecan-hziy, or carboplatin. The study includes a dose-escalation phase to determine the recommended phase 2 dose and a dose-expansion phase to assess antitumor activity. Different cohorts receive AVZO-021 alone or combined with these agents depending on their cancer type and treatment history. During the study, participants undergo regular evaluations including monitoring for dose-limiting toxicities and treatment-emergent adverse events. Pharmacokinetic assessments are performed during the first cycle to measure drug concentration and metabolism. Researchers measure tumor response, progression-free survival, overall survival, and duration of response. Safety and laboratory tests are conducted throughout the study. Participation may last several months or longer depending on treatment response and tolerability.
CONDITIONS
Brief Title
Study of AVZO-021 in Patients With Advanced Solid Tumors
Research Team
M
Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here